Boardroom Alpha
8-K primary document
AXR · Current Report (Form 8-K) · Filed March 12, 2026

Amrep Corp8-K exhibit

tm268363d1_ex99-1.htm

 

Exhibit 99.1

 

FOR:  AMREP Corporation
  850 West Chester Pike, Suite 205
  Havertown, PA 19083
 
CONTACT: Adrienne M. Uleau
  Chief Financial Officer and Vice President
  (610) 487-0907

 

AMREP REPORTS THIRD QUARTER FISCAL 2026 RESULTS

 

Havertown, Pennsylvania, March 12, 2026 – AMREP Corporation (NYSE:AXR) today reported net income of $3,147,000, or $0.58 per diluted share, for its 2026 fiscal third quarter ended January 31, 2026 compared to net income of $717,000, or $0.13 per diluted share, for the same period of the prior year. For the first nine months of 2026, AMREP had net income of $9,039,000, or $1.68 per diluted share, compared to net income of $8,823,000, or $1.64 per diluted share, for the same period of 2025. Revenues were $14,573,000 and $41,823,000 for the third quarter and first nine months of 2026 and $7,520,000 and $38,516,000 for the third quarter and first nine months of 2025.

 

More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which have today been filed with the Securities and Exchange Commission and will be available on AMREP’s website (www.amrepcorp.com/sec-filings/). As a result of many factors, including the nature and timing of specific transactions and the type and location of land or homes being sold, revenues, average selling prices and related gross margins from land sales or home sales can vary significantly from period to period and prior results are not necessarily a good indication of what may occur in future periods.

 

AMREP Corporation, through its subsidiaries, is a major holder of land, leading developer of real estate and award-winning homebuilder in New Mexico.

 

FINANCIAL HIGHLIGHTS

 

   Three Months Ended January 31, 
   2026   2025 
Revenues  $14,573,000   $7,520,000 
           
Net income  $3,147,000   $717,000 
Earnings per share – basic  $0.59   $0.13 
Earnings per share – diluted  $0.58   $0.13 
           
Weighted average number of common shares outstanding – basic   5,340,000    5,321,000 
Weighted average number of common shares outstanding – diluted   5,389,000    5,381,000 

 

   Nine Months Ended January 31, 
   2026   2025 
Revenues  $41,823,000   $38,516,000 
           
Net income  $9,039,000   $8,823,000 
Earnings per share – basic  $1.69   $1.66 
Earnings per share – diluted  $1.68   $1.64 
           
Weighted average number of common shares outstanding – basic   5,334,000    5,316,000 
Weighted average number of common shares outstanding – diluted   5,384,000    5,376,000 

 

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer